TRT — a data-driven guide

When TRT is clinically indicated

The Endocrine Society's 2018 clinical practice guideline (with 2023 updates) defines male hypogonadism — the clinical condition for which TRT is appropriate — as the combination of:

1. Symptoms consistent with androgen deficiency — typically including decreased libido, erectile dysfunction, reduced energy, depressed mood, reduced muscle mass and strength, loss of body hair, gynecomastia, or reduced bone density.
2. Unequivocally low serum testosterone — typically defined as a total testosterone below 264 to 300 ng/dL on at least two separate morning measurements, drawn fasting between 8 and 10 AM, when testosterone is at its diurnal peak.

Both conditions need to be present. Low testosterone on a single afternoon blood draw, without consistent symptoms, is not hypogonadism. Mild symptoms without consistently low testosterone is not hypogonadism either. The two-measurement requirement exists because testosterone has substantial day-to-day and within-day variability — a single low value frequently normalizes on repeat draw.

The diagnostic precision matters because the alternative — starting TRT in a man who has age-related but not pathologically low testosterone — commits him to potentially lifelong therapy with monitoring requirements and side-effect risks that don't carry the benefit of treating actual hypogonadism.

What proper monitoring looks like

Once TRT is started, monitoring requirements are not optional. The published guidelines and the practical clinical reality:

• Hematocrit and CBC. Testosterone stimulates erythropoiesis. Roughly 10 to 25 percent of men on TRT develop erythrocytosis (hematocrit above 52 to 54 percent), which increases risk of thrombotic events. Monitoring at 3 months, 6 months, then every 6 to 12 months is standard. If hematocrit climbs into the dangerous range, the response is dose reduction, switching modality, or therapeutic phlebotomy — not continuing without adjustment.
• Estradiol. Testosterone is aromatized to estradiol; supratherapeutic levels can cause gynecomastia, fluid retention, mood changes, and elevated cardiovascular risk. Monitoring estradiol on a sensitive assay is part of proper dose calibration.
• PSA and prostate exam. Annual PSA for men 40 and older, with attention to PSA velocity (rapid rises trigger urology referral). The historic concern about TRT and prostate cancer has softened in recent literature, but appropriate prostate-cancer screening within TRT remains standard.
• Symptom response. If a man on TRT for 6 months has no symptom improvement despite restored testosterone levels, the original symptoms probably weren't from hypogonadism. The right move in that case is to consider stopping, not to add more testosterone.
• Cardiovascular and metabolic markers. Lipids, blood pressure, glucose. TRT does not typically improve cardiovascular markers dramatically, but it shouldn't worsen them either.
• Fertility. TRT suppresses spermatogenesis through negative feedback on LH/FSH. If a man wants to preserve fertility, treatment with hCG, clomiphene, or enclomiphene is typically used either instead of or alongside testosterone — a conversation that should happen before starting therapy, not in retrospect.

A monitoring schedule that consists of "ship the next batch every 90 days" is not monitoring. It's a refill cadence.

The "low-normal optimization" problem

A substantial share of men currently on TRT have total testosterone in the low-normal range (300 to 500 ng/dL) rather than frank hypogonadism (below 264 to 300 ng/dL). These men typically present with symptoms — fatigue, reduced libido, lower mood — that overlap with hypogonadism but also overlap with poor sleep, obesity, thyroid dysfunction, depression, chronic stress, and the normal age-related decline of testosterone.

The case for treating low-normal men with TRT is weak in the published guidelines. The Endocrine Society explicitly does not recommend TRT for men with age-related decline alone. Studies of TRT in low-normal men have generally shown small symptom improvements at the cost of all the same monitoring requirements and side-effect risks as TRT for true hypogonadism.

The more rigorous approach for a low-normal man with symptoms is to work up the reversible contributors first — sleep apnea (very high prevalence in men with low-normal T), obesity, thyroid dysfunction, vitamin D deficiency, alcohol use, depression, medications that suppress T (opioids, glucocorticoids) — and to address those before committing to TRT. The yield from this workup is often higher than the yield from starting testosterone.

Some men will still meet the criteria for a TRT trial after a careful workup. Others will resolve their symptoms by treating the underlying contributor. The point of the workup is to distinguish them.

The fertility conversation

Exogenous testosterone suppresses LH and FSH via negative feedback, which suppresses endogenous testicular testosterone production and spermatogenesis. The clinical translation: most men on TRT experience reduced sperm production, and a substantial minority become functionally azoospermic. Fertility usually recovers after stopping TRT, but not always, and recovery may take months to years.

For men who want to preserve fertility (typically men under 40 who are not done having children), the appropriate options include:

• Clomiphene citrate or enclomiphene — oral selective estrogen receptor modulators that stimulate the body's own testosterone production by blocking estrogen feedback at the hypothalamus. Effective for many men with secondary hypogonadism and preserves fertility.
• hCG monotherapy — stimulates testicular testosterone production directly. Preserves fertility but is more expensive and requires injection.
• TRT plus hCG — combined approach for men who need TRT-level testosterone but want to preserve fertility.
• Sperm cryopreservation before starting TRT — appropriate for men with imminent or eventual desire to father children.

This conversation should happen at the diagnostic stage, not at month six when a couple is trying to conceive. The telehealth-mill model rarely addresses fertility proactively.

What we offer, plainly

TRT evaluation and management at Private MD is part of Direct Primary Care ($149/month) and Concierge Internal Medicine ($349/month) memberships, available when clinically indicated. The full diagnostic workup runs through our wholesale Quest contract; FDA-approved testosterone cypionate is prescribed through standard cash-pay pharmacies (Cost Plus Drugs and similar) at $30 to $80 per month. Monitoring labs at 3 months, 6 months, then every 6 to 12 months are included at wholesale.

If you're already on TRT through a telehealth platform and want a second-opinion review with proper monitoring, that's a common reason patients reach out. We can review your current regimen, run the monitoring labs you may not have had recently, and either continue your current dosing or recommend changes based on what the data shows.

About the author

Nishant Sahni, MD is board-certified in Internal Medicine and the founder of Private MD, a small-panel direct primary care and concierge longevity practice serving Granite Bay, Folsom, El Dorado Hills, and the greater Sacramento area. Former faculty at Mayo Clinic and the University of Minnesota.

Sources: Endocrine Society Clinical Practice Guideline on Testosterone Therapy in Men With Hypogonadism (2018, updated 2023); Lincoff AM et al., "Cardiovascular Safety of Testosterone-Replacement Therapy" (TRAVERSE trial), New England Journal of Medicine 2023; American Urological Association guideline on Evaluation and Management of Testosterone Deficiency (2018, updated 2023); published practice patterns in direct-to-consumer TRT prescribing. Cited figures reflect publicly available data as of May 2026. This article is for educational purposes and is not a substitute for individualized medical advice or evaluation.